All In Biotech

Drug Trial Radar · NCT06245330

A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Correlation With AKR1C3 Enzyme Expression of AST-001 in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Jul 7, 2022

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Sponsor type
Industry
First posted
Feb 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.

Conditions

  • Solid Tumor
  • Pancreatic Cancer

Interventions

  • AST-001Drug

    liquid formulation for Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AEs)Time frame: Adverse events will be noted as it occurs. Timeframe for measure begins after informed consent until 30 days after last dose of study drug.
  2. Assess safety changes in electrocardiogram (ECG)Time frame: Day 1 of each cycle(there are 26 cycles; 28 days for each cycle)
  3. Assess safety changes of body weight.Time frame: pre-AST-001 infusion of each cycle (there are 26 cycles; 28 days for each cycle)
  4. Number of participants with dose limiting toxicities (DLTs)Time frame: Throughout Cycle 1 (28 days for each cycle)
  5. Define the Recommended Phase 2 Dose (RP2D)Time frame: Days 1, 8 and 15 of each cycle (all 26 cycles and there are 28 days for each cycle)
  6. Pharmacokinetics (PK) - Time to maximum concentration (Tmax)Time frame: Days 1 and 15 of Cycle 1 (first cycle of 26 cycles and there are 28 days for each cycle)
  7. PK - Maximum peak plasma concentration (Cmax)Time frame: Days 1 and 15 of Cycle 1 (first cycle of 26 cycles and there are 28 days for each cycle)
  8. PK - Area under the concentration-time curve (AUClast) PK - Area under the concentration-time curve (AUClast)Time frame: Days 1 and 15 of Cycle 1 (first cycle of 26 cycles and there are 28 days for each cycle)
  9. PK - Half-life (T1/2)Time frame: Days 1 and 15 of Cycle 1 (first cycle of 26 cycles and there are 28 days for each cycle)
  10. Efficacy: Objective response rate(ORR)Time frame: up to 26 cycles (there are 28 days for each cycle)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jinlin Cancer Hospital

    Changchun, Jinlin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.